TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02571413

Intervention type: OTHER
Group type: OTHER
Intervention: score before teaching
Description: score the check-point of correct INCS usage before teaching

Intervention type: OTHER
Group type: OTHER
Intervention: score immediately after teaching
Description: score the check-point of correct INCS usage immediately after teaching

Intervention type: OTHER
Group type: OTHER
Intervention: score immediately after teaching
Description: score the check-point of correct INCS usage immediately after teaching

Intervention type: OTHER
Group type: OTHER
Intervention: score 3 months after teaching
Description: score the check-point of correct INCS usage 3 months after teaching
Study: NCT00835978

Intervention type: DRUG
Group type: OTHER
Intervention: axitinib
Description: axitinib 5mg BID (open-label) + placebo dose titration (blinded)
Study: NCT02571413

Intervention type: OTHER
Group type: OTHER
Intervention: score 3 months after teaching
Description: score the check-point of correct INCS usage 3 months after teaching
Study: NCT04036617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaQuinate
Description: SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
Study: NCT03729596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Anti-B7H3 antibody drug conjugate
Study: NCT02803502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronometric method
Description: Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chromogenic method
Description: Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombin generation test (TGT)
Description: Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used.
Study: NCT00835978

Intervention type: DRUG
Group type: OTHER
Intervention: axitinib
Description: axitinib 5mg BID (open-label)
Study: NCT01046318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-262
Description: OPC-262 5 mg will be orally administered once daily fro 52 weeks.
Study: NCT02465060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies
Study: NCT01175928

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
Study: NCT02465060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies
Study: NCT01175928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NormaTec PCD (Peristaltic Pulse PCD)
Description: Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
Study: NCT02638181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trabeculectomy
Study: NCT01701700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: portable electronic magnifier
Study: NCT02465060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies
Study: NCT01701700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: optical aids

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optical aids
Study: NCT05191082

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palatal Wound treated with Silk Fibroin Film
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palatal Wound treated with Neurotensin-loaded Silk Fibroin Film
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with neurotensin and 4.0 silk sutures.
Study: NCT04176510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coach Intervention
Description: A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
Study: NCT01408238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Four different concentrations of Secale cereale allergen extract, positive control and negative control
Description: 4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
Study: NCT02857712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
Study: NCT04732377

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erector spinae block with bupivacaine
Description: Group (A) (control group):~Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block with bupivacaine and dexmedetomidine
Description: Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
Study: NCT00834548

Intervention type: PROCEDURE
Intervention: Whole body magnetic resonance angiography (WB-MRA)
Description: WB-MRA will be performed once in each patient.

Intervention type: PROCEDURE
Intervention: Whole body magnetic resonance angiography (WB-MRA)
Description: WB-MRA will be performed once in each patient.
Study: NCT02329925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Stabilizing Device (TSD)
Description: Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
Study: NCT05316363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT
Description: Suboccipital Release - Finger pads are placed onto suboccipital musculature and a smooth, gentle, and rhythmic laterocephalad traction is applied to reduce muscle tension.~Paraspinal Inhibition - Hands are placed under the patient's thoracolumbar spine and contract the erector spinae tissue to draw the thoracolumbar spine into extension and hold until relaxation is felt.~Rib Raising - Hands are placed under the subject's thorax and contact the rib angles with finger pads. Fingers are flexed while adding an anteriolateral traction directed at the rib angle while maintaining neutral wrists. Arms are used as a lever by leaning forward thus creating a fulcrum with the treatment table with a smooth, rhythmic motion. This motion is repeated several times throughout the entire thoracic region, unilaterally and then switch sides.~Diaphragm Release - Hands apply a gentle pressure until a barrier or point of ease of the fascia is felt and hold that position until tissue response is felt.
Study: NCT02638012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floseal
Description: Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packing
Description: If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
Study: NCT00506389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
Study: NCT03697239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 25, 37.5, 56.25 or 75 grams/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein-bound
Description: 125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 in 500\*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 in 500\*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
Study: NCT05059197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP collagen peptide
Description: Health functional food

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00003323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: finasteride
Description: 5 mg/d PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: 250 mg PO tid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Assessment survey administered at baseline, and 3 \& 6 months post initiation of treatment
Study: NCT04600999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]
Study: NCT00188539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-treatment tumour oxygen measurements (under anesthesia)
Study: NCT03774680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab nanoparticles
Description: The active group will receive cetuximab in nanoparticles as an anti-microbial drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral approved anticancer drug
Description: The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
Study: NCT01067963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer assisted education and motivational interviewing.
Description: 9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group talks/social chat
Description: 9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
Study: NCT03757845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: subjects will be asked to eat from a sub-menu items compliant with Mediterranean Diet
Study: NCT03162315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freeze all
Study: NCT00844922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900636
Description: Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02566850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso
Description: powered lower extremity exoskeleton
Study: NCT04452786

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic sleeve gastroplasty
Description: Four-hour solid mixed meal test

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic sleeve gastrectomy
Description: Four-hour solid mixed meal test
Study: NCT02815566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir-alafenamide-emtricitabine
Description: comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir-emtricitabine
Description: comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
Study: NCT03750903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and Balance Training
Description: Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
Study: NCT03249454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
Study: NCT01013753

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) high
Description: Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) medium
Description: Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study: NCT02347358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JRecanTM blood FR device
Description: JRecanTM blood flow recanalisation device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV r-tPA
Description: intravenous recombinant human tissue plasminogen activator
Study: NCT01013753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) very low
Description: Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 mcg
Description: Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
Study: NCT04430348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: Monoclonal antibody PTX-35
Study: NCT01013753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) low
Description: Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study: NCT00906581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Problem-Solving Treatment
Description: 6 sessions of problem-solving treatment delivered via computer
Study: NCT04430348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: Monoclonal antibody PTX-35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: Monoclonal antibody PTX-35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: Monoclonal antibody PTX-35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: Monoclonal antibody PTX-35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: Monoclonal antibody PTX-35
Study: NCT04630314

Intervention type: DEVICE
Intervention: Percutaneus Coronary Intervention
Description: Covered Stent
Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
Study: NCT01764581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tacrolimus regulation according to ImmuKnow values
Description: Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event